Financing channel feed – Endpoints News

Financing channel feed

Google’s data-crunching mavens at GV buy in to Decibel’s R&D program for hearing loss, tinnitus

8 years ago

Medicxi’s new fund jumps off the beaten biotech path to lead a $30M round for diabetes program

8 years ago

Fast-moving Sienna Bio vaults from buyout to B round to $75M IPO

8 years ago

Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul

8 years ago

Atlas Venture vows to keep doing well by doing good with its new, $350M biotech fund

8 years ago

Mersana scores a $75M IPO as Wall Street continues to embrace biotech

8 years ago

With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M

8 years ago

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality

8 years ago

Langer-backed Sigilon sets sail with $23M and new ‘living’ cell therapy tech

8 years ago

Rubius lands $120M bonanza to fund a groundbreaking pipeline effort on a new drug platform

8 years ago

Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch

8 years ago

Biotech crossover investor Foresite is lining up a $650M stake for the big gambles to come

8 years ago

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

8 years ago

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

8 years ago

Top JPMorgan investment banker brings his talents — and connections — to the biotech startup crew on board Flagship

8 years ago

Aileron Therapeutics files for a $69M IPO as new offerings heat up

8 years ago

Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech

8 years ago

BRIEF: Deciphera bags a $52M round to back its cancer drug pipeline work

8 years ago

Scientist-turned-VC: Kevin Bitterman takes his biotech hatching experience to a new role at Atlas

8 years ago

Bicycle Therapeutics banks a $52M B round for the next leg of the long R&D journey ahead

8 years ago

$420M fund comes to LYFE, with plans for a trans-Pacific investment strategy introducing US biotechs to China

8 years ago

Ge Li melds WuXi VC with Frontline, creating an $800M trans-Pacific powerhouse fund now hunting fresh biotech capital

8 years ago

Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform

8 years ago

Ge Li’s fast-growing WuXi Biologics sets the stage for a $513M IPO

8 years ago

First page Previous page 138 139 140141142 143 144 Next page Last page